These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36864622)

  • 1. A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjögren's syndrome.
    Bentley D; Fisher BA; Barone F; Kolb FA; Attley G
    Rheumatology (Oxford); 2023 Nov; 62(11):3644-3653. PubMed ID: 36864622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
    Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren syndrome.
    Hargreaves P; Daoudlarian D; Theron M; Kolb FA; Manchester Young M; Reis B; Tiaden A; Bannert B; Kyburz D; Manigold T
    Arthritis Res Ther; 2019 Jul; 21(1):175. PubMed ID: 31319889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
    Baer AN; Gottenberg JE; St Clair EW; Sumida T; Takeuchi T; Seror R; Foulks G; Nys M; Mukherjee S; Wong R; Ray N; Bootsma H
    Ann Rheum Dis; 2021 Mar; 80(3):339-348. PubMed ID: 33168545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study.
    Price E; Bombardieri M; Kivitz A; Matzkies F; Gurtovaya O; Pechonkina A; Jiang W; Downie B; Mathur A; Mozaffarian A; Mozaffarian N; Gottenberg JE
    Rheumatology (Oxford); 2022 Nov; 61(12):4797-4808. PubMed ID: 35377447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
    Juarez M; Diaz N; Johnston GI; Nayar S; Payne A; Helmer E; Cain D; Williams P; Devauchelle-Pensec V; Fisher BA; Giacomelli R; Gottenberg JE; Guggino G; Kvarnström M; Mariette X; Ng WF; Rosas J; Sánchez Bursón J; Triolo G; Barone F; Bowman SJ
    Rheumatology (Oxford); 2021 Mar; 60(3):1364-1375. PubMed ID: 32949140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients.
    Bai W; Yang F; Xu H; Wei W; Li H; Zhang L; Zhao Y; Shi X; Zhang Y; Zeng X; Leng X
    Trials; 2023 Feb; 24(1):112. PubMed ID: 36793118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
    Dörner T; Kaul M; Szántó A; Tseng JC; Papas AS; Pylvaenaeinen I; Hanser M; Abdallah N; Grioni A; Santos Da Costa A; Ferrero E; Gergely P; Hillenbrand R; Avrameas A; Cenni B; Siegel RM
    Ann Rheum Dis; 2024 Feb; 83(3):360-371. PubMed ID: 37932009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
    Fisher BA; Mariette X; Papas A; Grader-Beck T; Bootsma H; Ng WF; van Daele PLA; Finzel S; Noaiseh G; Elgueta S; Hermann J; McCoy SS; Akpek E; Bookman A; Sopala M; Montecchi-Palmer M; Luo WL; Scheurer C; Hueber W;
    Lancet; 2024 Aug; 404(10452):540-553. PubMed ID: 39096929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of telitacicept in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial.
    Xu D; Fang J; Zhang S; Huang C; Huang C; Qin L; Li X; Chen M; Liu X; Liu Y; Li Z; Hu J; Bao C; Wei W; Tian J; Duan X; Zeng X
    Rheumatology (Oxford); 2024 Mar; 63(3):698-705. PubMed ID: 37399108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.
    Bowman SJ; Everett CC; O'Dwyer JL; Emery P; Pitzalis C; Ng WF; Pease CT; Price EJ; Sutcliffe N; Gendi NST; Hall FC; Ruddock SP; Fernandez C; Reynolds C; Hulme CT; Davies KA; Edwards CJ; Lanyon PC; Moots RJ; Roussou E; Giles IP; Sharples LD; Bombardieri M
    Arthritis Rheumatol; 2017 Jul; 69(7):1440-1450. PubMed ID: 28296257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
    Liu X; Li X; Li X; Li Z; Zhao D; Liu S; Zhang M; Zhang F; Zhu P; Chen J; Wei W; Lin B; Zhou Y; Chen J; Pang Y; Zhang L; Sun X; Yu Z; Jia Y; Wang J; Sun W; Chiu F; Pang L; Wang G
    Clin Rheumatol; 2019 Mar; 38(3):657-664. PubMed ID: 30280368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial.
    He J; Chen J; Miao M; Zhang R; Cheng G; Wang Y; Feng R; Huang B; Luan H; Jia Y; Jin Y; Zhang X; Shao M; Wang Y; Zhang X; Li J; Zhao X; Wang H; Liu T; Xiao X; Zhang X; Su Y; Mu R; Ye H; Li R; Liu X; Liu Y; Li C; Liu H; Hu F; Guo J; Liu W; Zhang WB; Jacob A; Ambrus JL; Ding C; Yu D; Sun X; Li Z
    JAMA Netw Open; 2022 Nov; 5(11):e2241451. PubMed ID: 36355371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
    Dörner T; Posch MG; Li Y; Petricoul O; Cabanski M; Milojevic JM; Kamphausen E; Valentin MA; Simonett C; Mooney L; Hüser A; Gram H; Wagner FD; Oliver SJ
    Ann Rheum Dis; 2019 May; 78(5):641-647. PubMed ID: 30826774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study.
    Fisher BA; Szanto A; Ng WF; Bombardieri M; Posch MG; Papas AS; Farag AM; Daikeler T; Bannert B; Kyburz D; Kivitz AJ; Carsons SE; Isenberg DA; Barone F; Bowman SJ; Espié P; Floch D; Dupuy C; Ren X; Faerber PM; Wright AM; Hockey HU; Rotte M; Milojevic J; Avrameas A; Valentin MA; Rush JS; Gergely P
    Lancet Rheumatol; 2020 Mar; 2(3):e142-e152. PubMed ID: 38263652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome--a double blind, randomised clinical trial.
    Norheim KB; Harboe E; Gøransson LG; Omdal R
    PLoS One; 2012; 7(1):e30123. PubMed ID: 22253903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acupuncture for Primary Sjögren Syndrome (pSS) on symptomatic improvements: study protocol for a randomized controlled trial.
    Jiang Q; Zhang H; Pang R; Chen J; Liu Z; Zhou X
    BMC Complement Altern Med; 2017 Jan; 17(1):61. PubMed ID: 28103850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
    Delli K; Haacke EA; Kroese FG; Pollard RP; Ihrler S; van der Vegt B; Vissink A; Bootsma H; Spijkervet FK
    Ann Rheum Dis; 2016 Nov; 75(11):1933-1938. PubMed ID: 26757748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial.
    Felten R; Devauchelle-Pensec V; Seror R; Duffau P; Saadoun D; Hachulla E; Pierre Yves H; Salliot C; Perdriger A; Morel J; Mékinian A; Vittecoq O; Berthelot JM; Dernis E; Le Guern V; Dieudé P; Larroche C; Richez C; Martin T; Zarnitsky C; Blaison G; Kieffer P; Maurier F; Dellal A; Rist S; Andres E; Contis A; Chatelus E; Sordet C; Sibilia J; Arnold C; Tawk MY; Aberkane O; Holterbach L; Cacoub P; Saraux A; Mariette X; Meyer N; Gottenberg JE
    Ann Rheum Dis; 2021 Mar; 80(3):329-338. PubMed ID: 33208345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
    Shao Q; Wang S; Jiang H; Liu L
    Scand J Rheumatol; 2021 Mar; 50(2):143-152. PubMed ID: 33118847
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.